The clinical efficacy and safety of Apatinib combined with radiotherapy and chemotherapy in the patients with medium-and late-stage cervical cancer / 中华老年医学杂志

ABSTRACT

Objective:To analyze the clinical efficacy and safety of Apatinib combined with radiotherapy and chemotherapy in patients with medium-and late-stage cervical cancer.Methods:A total of 58 patients with medium-and late-stage cervical cancer treated in our hospital from December 2017 to December 2020 were randomly divided into the control group(receiving the radiotherapy plus chemotherapy, n=29)and the observation group(receiving Lapatinib combined with radiotherapy plus chemotherapy, n=29). After 4 courses of continuous medication, the recent clinical efficacy, changes in tumor lesions, and adverse reactions were compared between the two group.Results:Before treatment, there was no significant difference in the size of tumor lesions between the two groups[(4.26±0.21)cm vs.(4.30±0.29)cm, P=0.550]. The tumor lesion size after treatment was significantly smaller both in observation group[(4.26±0.21) vs.(2.37±0.17)cm, P<0.01]and in the control group[(4.30±0.29) vs.(3.32±0.20)cm, P<0.01]. But image features revealed significantly smaller tumor lesion size in observation group than in the control group[(2.37±0.17)cm vs.(3.32±0.20)cm, P=0.000]. After treatment, the short-term total effective rates were significantly higher in the observation group(82.76%, 24/29)than in the control group(58.62%, 17/29), ( χ2=4.077, P=0.043). There was no statistical difference between the groups in incidences of diarrhea, rash, proteinuria, bone marrow suppression, hand-foot syndrome, hypertension, etc. Conclusions:The treatment of Lapatinib combined with radiotherapy and chemotherapy can effectively improve the clinical efficacy and reduce the size of the tumor lesions, and the adverse reactions can be tolerated in patients with medium-and late-stage cervical cancer.